Abstract
The role of percutaneous renal mass biopsy has continued to grow in the last decade. The incidence of small (≤4cm) renal masses has increased dramatically over the past 15 years, attributed to increased use of cross-sectional imaging and subsequent discovery of small renal masses that would otherwise go undetected. Despite increased early detection, there has been no change in the mortality rate from renal cell carcinoma over the past 15 years. Many small renal masses are not life-limiting, and imaging lacks specificity in distinguishing malignant from nonmalignant small renal masses. Thus, percutaneous biopsy has emerged as an integral part of the diagnosis of renal masses in order to better guide their management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
